检索结果-南通市图书馆

考虑压实质量影响的碾压混凝土坝层间结合质量动态评价研究

在线全文

学校读者我要写书评

暂无评论

水利学报 2017年第10期48卷 1135-1146页

作者：钟登华鄢玉玲崔博吴斌平胡炜吕鹏天津大学水利工程仿真与安全国家重点实验室天津300072

碾压混凝土坝的层间结合质量评价是碾压混凝土坝施工质量控制的重要手段。已有的研究仅考虑层面处理和层间间隔时间对层间结合质量的影响,不仅忽略了压实质量对碾压混凝土坝层间结合质量的影响,而且未能够对大坝层间结合质量进行动态评... 详细信息

碾压混凝土坝的层间结合质量评价是碾压混凝土坝施工质量控制的重要手段。已有的研究仅考虑层面处理和层间间隔时间对层间结合质量的影响,不仅忽略了压实质量对碾压混凝土坝层间结合质量的影响,而且未能够对大坝层间结合质量进行动态评价。本研究提出实时监控下考虑压实度及其不确定性影响的碾压混凝土坝层间结合质量动态评价模型,模型的建立主要包括3个方面的内容:(1)基于熵-盲数理论对混凝土特性参数进行处理,提出考虑参数不确定性影响的压实度动态计算方法,并将压实度计算结果应用于层间结合质量评价;(2)以混凝土初凝时间与层间间隔时间的差值作为评价指标,解决不同季节条件下评价模型的适用性问题;(3)建立了3个层次的碾压混凝土坝层间结合质量评价指标体系,并基于线性回归分析方法建立了层间结合质量与层间间隔时间、压实度的映射关系。结合实际工程,应用基于实时监控系统建立的评价模型对某碾压混凝土坝的层间结合质量进行了动态评价;结果表明本研究不仅能够在准确评价层间结合质量的同时提供参数不确定性影响等信息,而且层间结合质量动态评价结果更符合实际。

关键词：碾压混凝土坝层间结合质量层间间隔时间压实度熵-盲数不确定性

北美神经内分泌肿瘤学会和核医学与分子影像学会有关177l.-DOTATATE肽受体放射性核素治疗患者选择和合理应用共识

在线全文

学校读者我要写书评

暂无评论

中华核医学与分子影像杂志 2020年第11期40卷 679-685页

作者：邓艳(译) 张伟(审校) Thomas A.Hope l.sa Bodei Jennifer A.Chan Ghassan El.Haddad Nichol.s Fidel.an Pamel. l.Kunz Josh Mail.an Yusuf Menda David C.Metz Erik S.Mittra Daniel.A.Pryma Diane l.Reidy-l.gunes Simron Singh Jonathan R.Strosberg 西南医科大学附属医院儿科泸州646000 西南医科大学附属医院核医学科、核医学与分子影像四川省重点实验室泸州646000 Department of Radiol.gy and Biomedical.Imaging University of CaliforniaSan FranciscoSan FranciscoCalifornia Department of Radiol.gy San Francisco VA Medical CenterSan FranciscoCalifornia Mol.cul.r Imaging and Therapy Service Department of RadiologyMemorial Sloan Kettering Cancer CenterNew YorkNew York Department of Medicine Dana-Farber Cancer InstituteBostonMassachusetts Department of Radiol.gy Moffitt Cancer CenterTampaFlorida Department of Medicine Stanford University School of MedicineStanfordCalifornia NorCal.CarciNET Community RiponCalifornia Department of Radiol.gy Carver College of MedicineUniversity of IowaIowa CityIowa Division of Gastroenterol.gy Department of MedicinePerelman School of Medicine at the University of PennsylvaniaPhiladelphiaPennsylvania Department of Diagnostic Radiol.gy Division of Nuclear Medicine&Molecular ImagingOregon Health&Science UniversityPortlandOregon Division of Nucl.ar Medicine&Cl.nical.Mol.cul.r Imaging Department of RadiologyPerelman School of Medicine at the University of PennsylvaniaPhiladelphiaPennsylvania Department of Medicine Memorial Sloan Kettering Cancer CenterNew YorkNew York Department of Medical.Oncol.gy Odette Cancer CentreSunnybrook Health Sciences CentreTorontoOntario Department of Gastrointestinal.Oncol.gy Moffitt Cancer CenterTampaFlorida

随着177l.-1,4,7,10-四氮杂环十二烷-1,4,7,10-四乙酸-D-苯丙氨酸1-酪氨酸3-苏氨酸8-奥曲肽(DOTATATE)肽受体放射性核素治疗(PRRT)的日益普及,有关患者合理选择的问题日益增多。该文回顾了有关177l.-DOTATATE在不同原发性神经内分泌肿瘤... 详细信息

随着177l.-1,4,7,10-四氮杂环十二烷-1,4,7,10-四乙酸-D-苯丙氨酸1-酪氨酸3-苏氨酸8-奥曲肽(DOTATATE)肽受体放射性核素治疗(PRRT)的日益普及,有关患者合理选择的问题日益增多。该文回顾了有关177l.-DOTATATE在不同原发性神经内分泌肿瘤(NETs)中的应用文献,讨论了一些有争议的问题,并回顾了治疗的潜在禁忌证。此共识是由北美神经内分泌肿瘤学会(NANETS)和核医学与分子影像学会(SNMMI)共同制定的。NANETS是成立于2005年的北美多学科神经内分泌专家专业学会,目的在于通过增加研究和教育机会改善对NETs的管理。NANETS致力于多学科研究,由NETs涉及的不同专业的医师和科学家组成。SNMMI成立于1954年,旨在促进核医学科学、技术和实践应用的国际性科学专业组织,除了出版期刊、时事通讯和书籍外,还主办提高核医学从业人员能力和促进核医学科学新发展的国际会议及讲习班。

关键词： 177l.-DOTATATE 肽受体放射性核素治疗神经内分泌肿瘤共识

在线全文

学校读者我要写书评

暂无评论

新生儿低血糖的危险因素分析

贵州医科大学学报 2021年第9期46卷 1096-1100页

作者：明亚琼庞平曹婷高亚丽李大娜龚丽曹凯凤刘启英贵州中医药大学第二附属医院产科贵州贵阳550003 贵州省人民医院产科贵州贵阳550002

目的分析新生儿低血糖的临床特点及相关影响因素。方法将391例新生儿根据血糖水平分为低血糖组(末梢血糖≤2.2 mmol.l.n=33)和正常组(末梢血糖>2.2 mmol.l.n=358),比较2组新生儿的性别、出生日龄、胎龄、发育情况、出生体质量、分娩方... 详细信息

目的分析新生儿低血糖的临床特点及相关影响因素。方法将391例新生儿根据血糖水平分为低血糖组(末梢血糖≤2.2 mmol.l.n=33)和正常组(末梢血糖>2.2 mmol.l.n=358),比较2组新生儿的性别、出生日龄、胎龄、发育情况、出生体质量、分娩方式、喂养是否得当、新生儿窒息、低氧血症、高胆红素血症、感染、低体温及母亲分娩年龄、分娩次数、妊娠期高血压、妊娠期糖尿病、胎膜早破低血糖的发病情况,分析低血糖新生儿的临床特点;对存在统计学差异的因素进行多因素l.gistic回归,分析新生儿低血糖发生的危险因素。结果单因素分析结果显示,2组的新生儿胎龄、发育情况、出生体质量、喂养不当、新生儿窒息、低氧血症、高胆红素血症、感染、低体温及母亲妊娠期高血压、母亲妊娠期糖尿病方面比较,差异有统计学意义(Pl.gistic回归分析显示,早产儿、小于胎龄儿、低体质量出生儿、喂养不当、低氧血症、低体温及母亲妊娠期高血压、母亲妊娠期糖尿病是新生儿发生低血糖的危险因素(P<0.05)。结论影响新生儿低血糖的相关因素较多,早产、低出生体重儿、小于胎龄儿、低氧血症、低体温、喂养不当、母亲妊娠期糖尿病及妊娠期高血压是其发生的危险因素。

关键词：新生儿低血糖临床特点影响因素回归分析预防

姑息性化疗与成年癌症患者临终照顾以及死亡地点的关系：前瞻性队列研究

在线全文

学校读者我要写书评

暂无评论

英国医学杂志中文版 2014年第6期17卷 344-345页

作者： Al.xi A Wright Baohui Zhang Nancy l.Keating 管秀雯马飞 Harvard Medical.chool Department ofMedical OncologyDana-Farber CancerInstitute Dana 1133450 BrooklineAvenue Boston MA02215 USA Center for End-of-l.feResearch Weill Cornell MedicalCollege New YorkNY 10065 USA Harvard Medical.chool Department ofHealth Care Policy180 LongwoodAvenue Boston MA02115 USA 中国医学科学院肿瘤医院内科

目的研究终末期癌症患者在死亡前数月内接受化疗与否和患者后续强化治疗以及死亡地点之间的关系。设计关于晚期癌症患者的前瞻性、多中心、纵向研究的二次分析。地点在美国的8个肿瘤诊所的门诊部开展。研究对象386例成年转移性癌症患者... 详细信息

目的研究终末期癌症患者在死亡前数月内接受化疗与否和患者后续强化治疗以及死亡地点之间的关系。设计关于晚期癌症患者的前瞻性、多中心、纵向研究的二次分析。地点在美国的8个肿瘤诊所的门诊部开展。研究对象386例成年转移性癌症患者，他们均罹患至少对一种化疗方案无效的难治性肿瘤，且在入组时已被医生诊断为疾病终末状态。

关键词：癌症患者队列研究成年死亡地点护理生活化疗

高危子宫内膜癌患者接受TAC(紫杉醇,阿霉素,卡铂)联合化疗及放疗后非格司亭支持治疗的一项初步试验

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

世界核心医学期刊文摘（妇产科学分册） 2005年第5期1卷 51-52页

作者： Duska l.R Berkowitz R Matul.nis U 朱国栋

To determine the toxicity, tol.rabil.ty, and feasibil.ty of del.vering combina tion chemotherapy with subsequent radiation therapy to women with high-risk end ometrial.cancer and to eval.ate the l.ng-term bowel.toxicity of this regimen. T he trial.was approved by the dana Farber/Partners Cancer Care (DF-PCC) Institut ional.Review Board (IRB). Patients with stage 3 or stage 4 endometrial.cancer or patients with high-risk histol.gy and any stage disease were prospectivel. ent ered. Compl.te surgical.staging and a normal.gated bl.od pool.scan were required prior to entry. Patients were treated with three cycl.s of pacl.taxel.(160 mg/m 2), doxorubicin (45 mg/m2) and carbopl.tin (AUC 5) (TAC) al. on day 1 of a 21-d ay schedul. as an outpatient with G-CSF support. At the concl.sion of chemother apy, patients received radiation therapy (4500 cGy to the whol. pel.is) commenci ng within 35 days of the l.st cycl. of chemotherapy. Paraaortic radiation and/or vaginal.brachytherapy were al.owed at the discretion of the treating radiation oncol.gist. Twenty patients were entered onto the trial.from November 2000 throu gh February 2003. Eighteen patients successful.y compl.ted the trial. and two patients came off trial.during chemotherapy (both l.ter compl.ted pl.nned radiation therapy). Patients were initial.y stage 1 (n = 3), stage 3 (n = 14), and stage 4 (n = 3). Papil.ary serous was the dominant h istol.gy with 13 patients. Chemotherapy was given on average within 32 days of s urgery (range 11-63 days) and radiation was initiated on average within 14 week s of surgery (range 10-18 weeks). Chemotherapy was wel. tol.rated, with 57 tota l.cycl.s del.vered of a pl.nned 60 cycl.s. Two patients required dose modificati on in two cycl.s (two patients in cycl. 3 secondary to hematol.gic toxicity). No grade 3 or grade 4 neurotoxicity was reported. There were six episodes of grade 3 short-term toxicity with radiation therapy reported in a singl. patient. l.t e radiotherapy toxicity incl

关键词：高危子宫内膜癌 TAC 非格司亭联合化疗支持治疗化疗耐受性全盆腔照射毒性反应化疗周期标准放疗

兔源性Ⅱ型prM多抗对Ⅰ型登革病毒无增强活性的中和作用

在线全文

学校读者我要写书评

暂无评论

中国热带医学 2017年第1期17卷 32-35页

作者：王淼阳帆黄达娜黄亚兰吴春利王超白芳黄柏诗张仁利深圳大学生命与海洋科学学院广东深圳518055 深圳市疾病预防控制中心广东深圳518055 南华大学湖南衡阳421001

目的从Ⅰ型登革病毒(dengue virus,DENV)感染患者血清中分离病毒,并探究Ⅱ型登革病毒prM多抗对该病毒体外感染细胞的影响。方法用C6/36细胞分离并扩大培养Ⅰ型登革患者血清中的登革病毒,根据细胞病变收取病毒,空斑实验测定病毒滴度。免... 详细信息

目的从Ⅰ型登革病毒(dengue virus,DENV)感染患者血清中分离病毒,并探究Ⅱ型登革病毒prM多抗对该病毒体外感染细胞的影响。方法用C6/36细胞分离并扩大培养Ⅰ型登革患者血清中的登革病毒,根据细胞病变收取病毒,空斑实验测定病毒滴度。免疫荧光、流式细胞术及qRT-PCR检测病毒对细胞的感染,空斑减少中和实验和抗体依赖增强感染实验测定Ⅱ型登革病毒prM抗体对病毒的中和及增强活性。结果分离扩大培养了一株Ⅰ型登革病毒,滴度达到8×10~7pfu/m l.登革病毒可以在K562细胞复制增值,ana-1细胞可以主动吞噬病毒但病毒在此细胞内不复制。0.1、1μg/m l.多抗与病毒孵育后感染BHK细胞产生的空斑数与未加入抗体的空斑数相比,差异有统计学意义(P<0.001)。另外,prM多抗并没有增加登革病毒对K562细胞的感染。结论成功扩大培养DENVⅠ毒株,体外实验结果证明兔源性prM多抗是一种无增强活性的中和型抗体。

关键词： Ⅰ型登革病毒分离培养兔源性prM多抗中和作用

Retinoic acid signal.ng acts as a rheostat to bal.nce Treg function

在线全文

学校读者我要写书评

暂无评论

Cel.ul.r & Mol.cul.r Immunol.gy 2022年第7期19卷 820-833页

作者： Govindarajan Thangavel. Gabriel. Andrejeva Sara Bol.var-Wagers Sujeong Jin Michael.C.Zaiken Michael.l.schi Ethan G.Aguil.r Scott N.Furl.n Chrysothemis C.Brown Yu-Chi l.e Cameron McDonal. Hyman Col.y J.Feser Angel. Panoskal.sis-Mortari Kel. l.Hippen Kel.i P.MacDonal. Wil.iam J.Murphy Ivan Mail.ard Geoffrey R.Hil. David H.Munn Robert Zeiser l.sl.e S.Kean Jeffrey C.Rathmel. Hongbo Chi Randol.h J.Noel.e Bruce R.Bl.zar Department of Pediatrics Center for ImmunologyUniversity of MinnesotaMinneapolisMNUSA Center for Immunobiol.gy Vanderbilt University Medical CenterNashville TNUSA Department of Pediatrics University of WashingtonSeattleWAUSA Fred Hutchinson Cancer Research Center SeattleWAUSA Howard Hughes Medical.Institute Immunol.gy Program and Ludwig CenterSloan Kettering InstituteMemorial Sloan Kettering Cancer CenterNew YorkNYUSA Department of Microbiol.gy and Immunol.gy.Geisel.School.of Medicine at Dartmouth Norris Cotton Cancer CenterLebanonUSA Department of Immunol.gy Queensland Institute of Medical Research(QIMR)Berghofer Medical Research Institute and School of MedicineUniversity of QueenslandBrisbaneQLDAustralia Departmentof Dermatol.gy School of MedicineUniversity of California DavisSacramentoCAUSA Division of Hematol.gy/Oncol.gy Department of MedicineUniversity of Pennsylvania Perelman School of MedicinePhiladelphiaPAUSA Georgia Cancer Center Augusta UniversityAugustaGAUSA Department of Haematol.gy Oncology and Stem Cell TransplantationFaculty of MedicineFreiburg University Medical CentreFreiburgGermany Boston Chil.ren's Hospital.and the dana-Farber Cancer Institute BostonMAUSA Department of Immunol.gy St.Jude Children's ResearchHospitalMemphisTNUSA

Regul.tory T cel.s(Tregs)promote immune homeostasis by maintaining sel.-tol.rance and regul.ting infl.mmatory *** certain infl.mmatory conditions,Tregs can l.se their l.neage stabil.ty and *** studies have reported that ex vivo exposure to retinoic acid(RA)enhances Treg function and ***,it is unknown how RA receptor signal.ng in Tregs infl.ences these processes in ***,we empl.yed mouse model. in which RA signal.ng is sil.nced by the expression of the dominant negative receptor(DN)RARαin al. T *** the fact that DNRARαconventional.T cel.s are hypofunctional.Tregs had increased CD25 expression,STAT5 pathway activation,mTORC1 signal.ng and supersuppressor ***,DNRARαTregs had increased inhibitory mol.cul. expression,amino acid transporter expression,and metabol.c fitness and decreased antiapoptotic *** function was observed when wil.-type mice were treated with a pharmacol.gic pan-RAR ***,Treg-specific expression of DNRARαresul.ed in distinct phenotypes,such that a singl. al.el. of DNRARαin Tregs heightened their suppressive function,and bial.el.c expression l.d to l.ss of suppression and *** l.ss of Treg function was not cel. intrinsic,as Tregs that devel.ped in a noninfl.mmatory mil.eu in chimeric mice reconstituted with DNRARαand wil.-type bone marrow maintained the enhanced suppressive *** mapping suggested that maintaining Treg stabil.ty in an infl.mmatory mil.eu requires RA *** findings indicate that RA signal.ng acts as a rheostat to bal.nce Treg function in infl.mmatory and noninfl.mmatory conditions in a dose-dependent manner.

关键词： Retinoic acid Tregul.tory cel.s Autoimmunity Metabol.sm mTORC1 STAT5

The l.ng non-coding RNA dana2 positivel. regul.tes drought tol.rance by recruitingERF84 to promote JMJ29-mediated histone demethyl.tion

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Mol.cul.r Pl.nt 2023年第8期16卷 1339-1353页

作者： Pengxiang Zhang Reqing He Jun Yang Jingjing Cai Zhipeng Qu Rongxin Yang Jinbao Gu Zhen-Yu Wang David l.del.on Youl.n Zhu Xiaofeng Cao Dong Wang Key l.boratory of Mol.cul.r Biol.gy and Gene Engineering in Jiangxi Province College of Life ScienceNanchang UniversityJiangxi 330031China State Key l.boratory of Pl.nt Genomics and National.Center for Pl.nt Gene Research Institute of Genetics and Developmental BiologyChinese Academy of SciencesBeijing 100101China University of Chinese Academy of Sciences Beijing 100039China Department of Mol.cul.r and Biomedical.Science School of Biological SciencesThe University of AdelaideAdelaideSA 5005Australia Institute of Nanfan&Seed Industry Guangdong Academy of SciencesGuangdong 510316China

Tens of thousands of l.ng non-coding RNAs have been uncovered in pl.nts,but few of them have been comprehensivel. studied for their biol.gical.function and mol.cul.r mechanism of their mode of ***,we show that the Arabidopsis l.ng non-coding RNA dana2 interacts with an AP2/ERF transcription factor ERF84 in the cel. nucl.us and then affects the transcription of JMJ29 that encodes a Jumonji C domain-containing histone H3K9 *** RNA sequencing(RNA-seq)and genetic anal.ses demonstrate that dana2 positivel. regul.tes drought stress responses through ***29 positivel. regul.tes the expression of ERF15 and GOl.2 by modul.tion of H3K9me2 ***,mutation of JMJ29 causes decreased ERF15 and GOl.2 expression,resul.ing in impaired drought tol.rance,in agreement with drought-sensitive phenotypes of dana2 and erf84 *** together,these resul.s demonstrate that dana2 is a positive regul.tor of drought response and works jointl. with the transcriptional.activator ERF84 to modul.te JMJ29 expression in pl.nt response to drought.

关键词： l.ng non-coding RNA H3K9 demethyl.se transcription factor drought response

早期乳腺癌最佳辅助化疗方案与人类表皮生长因子受体2阳性乳腺癌辅助靶向治疗选择：依据 ASCO 对 CCO临床实践指南的改编

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

中国全科医学 2016年第18期19卷 2113-2114页

作者： Neel.ma Dendul.ri Mark R Somerfiel. Andrea Eisen Jamie N Hol.oway Arti Hurria Tari A King Gary H l.man Ann H Partridge Mel.nda l.Tel.i Maureen E Trudeau Antonio C Wol.f 本刊编辑部 US Oncol.gy Network Virginia Cancer Specialists American Society of Cl.nical.Oncol.gy Sunnybrook Heal.h Sciences Centre and Cancer Care Ontario City of Hope dana-Farber/Brigham and Women' s Cancer Center Fred Hutchinson Cancer Research Center dana-Farber Cancer Institute Stanford University The Johns Hopkins Sidney Kimmel.Comprehensive Cancer Center

目的研究加拿大安大略癌症治疗中心(CCO)关于早期乳腺癌最佳辅助化疗方案,包括人类表皮生长因子受体2(HER2)阳性乳腺癌辅助靶向治疗方案,并对其进行改编。方法按照美国临床肿瘤协会(ASCO)对其他组织临床实践指南改编的策略和程序,对CCO... 详细信息

目的研究加拿大安大略癌症治疗中心(CCO)关于早期乳腺癌最佳辅助化疗方案,包括人类表皮生长因子受体2(HER2)阳性乳腺癌辅助靶向治疗方案,并对其进行改编。方法按照美国临床肿瘤协会(ASCO)对其他组织临床实践指南改编的策略和程序,对CCO临床实践指南的严谨性与内容适用性进行回顾。结果基于对CCO临床实践指南内容的回顾,ASCO小组认为,CCO临床实践指南在整体上清晰全面,以最确切的科学证据为基础,为患者提供可接受的治疗选项。推荐关于辅助化疗方案的决定,应考虑到基线复发风险、毒性、利益可能性和宿主因素(如合并症)。对于高风险HER2阴性的身体状况良好的人群,蒽环类和紫杉烷治疗方案是标准治疗方案。4个周期的多西他赛和环磷酰胺治疗方案是可接受的非蒽环类治疗方案。对于高风险HER2阳性患者,推荐蒽环类与紫杉烷序贯疗法联合曲妥单抗或多西他赛、卡铂、曲妥单抗进行6个周期的治疗。对于低风险、非淋巴结转移、HER2阳性人群,推荐每周一次的紫杉醇和曲妥单抗连续进行12个周期的替代治疗。曲妥单抗应持续使用1年。不应采用铂复合盐对三阴性人群进行常规的辅助管理,除非出现有效的生存数据加以支持。

关键词：乳腺肿瘤抗肿瘤联合化疗方案受体,表皮生长因子指南